Genentech: Home

News & Features

		Growth Company A profitable growth company, Genentech has a strong and diverse pipeline with more than 100 projects in development.



		Accelerated Approval for Avastin in Breast Cancer On February 22, 2008, the FDA granted accelerated approval for Avastin in combination with paclitaxel chemotherapy for the first-line treatment of advanced HER2-negative breast cancer.

SCIENTIFIC LEADERSHIP >> Genentech's scientists are some of the most prolific in the industry and in their fields.



DEVELOPMENT PIPELINE >> Genentech's pipeline continues to grow, with more than 100 promising projects in development.

Genentech is committed to making sure price is not a barrier to access for patients.

FORTUNE magazine has named Genentech to its "100 Best Companies to Work For" and "America's Most Admired" lists.

Genentech's postdoctoral program offers the chance to do cutting-edge research in an inspiring environment.